Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Crohn’s Disease | Treatment Algorithms: Claims Data Analysis | Adult | US | 2021
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and…
Non-alcoholic Steatohepatitis | Treatment Algorithms: Claims Data Analysis | US | ALGOMD0032-2021
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…
Opioid Induced Constipation | Treatment Algorithms: Claims Data Analysis | US | 2021
The drug market for opioid induced constipation (OIC) is served by a variety of prescription medications, including several agents that are approved for irritable bowel syndrome with constipation (…
Systemic Lupus Erythematosus | Treatment Algorithms | Claims Data Analysis | US ALGOIM0041-2021
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious central nervous system and renal…
Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS Without Diarrhea (Including IBS-Constipation) | US | 2021
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Asthma | Treatment Algorithms: Claims Data Analysis | Pediatric Asthma | US | 2021
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as ProAir HFA or its generics) and maintenance therapy to…
Urticaria | Treatment Algorithms: Claims Data Analysis | Chronic Spontaneous | US | 2021
The drug market for chronic spontaneous urticaria (CSU), previously know as chronic idiopathic urticaria, is dominated by oral medications, including first- and second-generation (nondrowsy)…
Biomarkers in Oncology – Access & Reimbursement – Detailed, Expanded Analysis (US) Biomarkers in Oncology
Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malignant…
Chimeric Antigen Receptor (CAR) T-Cell Therapy | Access & Reimbursement | US | TBD | US | 2020
The approval two CAR T-cell therapies for relapsed / refractory B-cell hematological malignancies—Novatis’ Kymriah for acute lymphoblastic leukemia (ALL) and large B-cell lymphoma and Kite…
